Drug combination acts against aggressive chronic lymphocytic leukemia
Monday, December 10, 2012 - 19:30
in Health & Medicine
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial.